Our results provide a preclinical rationale for the combination of PARP inhibitors and TRAIL receptor agonists independent of BRCA2 mutation status in pancreatic cancer and may extend the limited applicability of PARP inhibitors in this disease. Here, PARP1 is linked to pancreatic neoplasm.